AML containing the t(8;21) translocation show exceptional sensitivity to flavopiridol and dinaciclib, two broad-spectrum cyclin-dependent kinase (CDK) inhibitors that have high potency against CDK9, both in vitro and in clinical trials (39,40). Here, CDK9 is linked to acute myeloid leukemia.